The MarketReader Minute
💊 Medpace Faces Legal Scrutiny, Centessa and Viking Tumble, While Soleno Surges on FDA Nod and AbbVie Boosts Community Impact | Biotech Sector Insights
Medpace Holdings, Inc. (MEDP) is under scrutiny due to a federal securities investigation linked to disappointing Q2 2024 financial results and lowered revenue guidance, resulting in a sharp decline in its stock price.